Physician profile
Mark William Miller
NPI 1659306439
$1,367.24
in general payments reported to CMS, 2019-2025
21 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.73 · 2020: $68.74 · 2021: $76.63 · 2023: $159 · 2024: $340 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.14 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $250.82 | 2023-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $210.16 | 2019-2025 | |
| Astellas Pharma US INC | $198.27 | 2023-2025 | Veozah |
| Inspire Medical Systems, INC. | $140.26 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $125.98 | 2020-2025 | |
| Lilly USA, LLC | $65.30 | 2025 | Zepbound |
| Amgen INC. | $45.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $41.43 | 2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $36.60 | 2024 | Xarelto |
| Zoll Respicardia, INC. | $29.94 | 2024 | Remede System |
| Aerin Medical INC. | $27.52 | 2025 | |
| Boston Scientific Corporation | $24.97 | 2021 | |
| Abbott Laboratories | $23.74 | 2023 | Cardiomems |
| Novo Nordisk INC | $23.34 | 2023 | Rybelsus, Ozempic |
| Atricure, INC. | $23.16 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.91 | 2023 | Injectafer |
| Eisai INC. | $20.73 | 2025 | |
| Myriad Genetic Laboratories, INC. | $19.56 | 2023 | Mychoice Cdx |
| Astrazeneca Pharmaceuticals LP | $14.52 | 2021 | |
| 3b Medical, INC. | $12.39 | 2025 | Luna |
| Resmed Corp | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.